Cardiovascular Risks Associated with Corticosteroid Use

Introduction to Cardiovascular Risks

• The European League Against Rheumatism (EULAR) guidelines emphasize that cardiovascular risk is higher with long-term high doses compared to low doses 1, 2
• Current oral corticosteroid users have an OR of 2.7 (1.9-3.8) for developing atrial fibrillation compared to non-users 3
• High-dose corticosteroids (≥7.5 mg prednisone equivalents) carry an OR of 6.07 (3.90-9.42) for atrial fibrillation 3

Atrial Fibrillation Risk

• Risk is particularly elevated in patients with rheumatic, allergic, or malignant hematologic diseases (OR 7.90; 4.47-13.98) 3, 4
• The relative risk is greatest at the beginning of therapy and with short-term use 3, 4
• Inhaled corticosteroids do not increase arrhythmia risk, and former corticosteroid use is not associated with increased atrial fibrillation risk 3, 4

Mechanisms of Corticosteroid-Induced Atrial Fibrillation

• Three primary pathways explain atrial fibrillation development: direct increase in cellular K+ efflux, mineralocorticoid-like effects, and long-term promotion of atherosclerosis, diabetes mellitus, hypertension, heart failure, and ischemic heart disease 3, 4, 5

Clinical Risk Stratification and Management

• The EULAR guidelines recommend using the lowest dose for the shortest period possible to minimize cardiovascular risk 1, 2
• No clear evidence that low-dose corticosteroids (<7.5 mg prednisone equivalent) significantly contribute to cardiovascular risk 1, 2
• Corticosteroids have paradoxical cardiovascular effects that must be balanced, including deleterious effects on lipids, glucose tolerance, and blood pressure, as well as protective effects on inflammation 1, 2

Route-Specific Considerations

• Inhaled corticosteroids have a more favorable cardiovascular profile, with less common systemic side effects 5
• Using spacers with metered dose inhalers reduces systemic absorption and associated side effects 5

Monitoring and Prevention

• Screen for and aggressively manage hypertension, dyslipidemia, and hyperglycemia to prevent cardiovascular risk 1, 2
• Consider cardiovascular risk assessment before initiating therapy, particularly in patients with pre-existing risk factors 1, 2
• Implement lifestyle modifications, including smoking cessation, to reduce cardiovascular risk 1, 2

Cardiovascular Risks Associated with Prednisone Use

Introduction to Cardiovascular Risks

• The American College of Cardiology states that long-term use of prednisone at doses ≥7.5 mg daily is associated with increased cardiovascular risk, including coronary artery disease, while short-term use (<81 days) or lower doses (<7.5 mg daily) do not appear to significantly increase this risk 6

Dose and Duration Thresholds

• The European Heart Journal reports that daily doses ≥7.5 mg prednisone or cumulative doses ≥40 g are associated with increased cardiovascular events, indicating a high-risk threshold 7
• The American College of Cardiology recommends that short courses of glucocorticoids for autoimmune disease flares are unlikely to increase cardiovascular risk, highlighting the importance of short-term safety 6

Mechanisms of Cardiovascular Risk

• The European Heart Journal notes that prednisone increases coronary artery disease risk through metabolic effects, including elevation of LDL cholesterol and increased triglycerides, with an increase of 7.5 mg in LDL cholesterol per 10 mg prednisone dose 7

Clinical Management Strategy

• The European Heart Journal suggests targeting doses <7.5 mg daily when feasible for patients requiring prednisone, to minimize dose and duration 7
• The American College of Cardiology and the European Heart Journal recommend considering steroid-sparing agents, such as DMARDs or other immunomodulators, to reduce prednisone requirements 6, 7

Special Populations

• The American College of Cardiology states that patients with rheumatoid arthritis or lupus have baseline elevated cardiovascular risk, and duration of prednisone use is an independent risk factor for later coronary artery disease in lupus cohorts 6
• The European Heart Journal advises that cardiovascular risk assessment should be performed before initiating therapy and repeated with substantial dose changes in these patient populations 7

Risk of Short-Course Steroids in Patients on Plavix

Evidence-Based Risk Assessment

• The American College of Rheumatology suggests that short courses of glucocorticoids (<81 days) or doses <7.5 mg daily prednisone equivalent do not appear to significantly increase cardiovascular risk, making a 5-day course relatively safe from a cardiovascular standpoint 8
• The European Society of Cardiology states that there is no pharmacological interaction between clopidogrel and corticosteroids that would alter clopidogrel's antiplatelet efficacy or increase bleeding risk beyond baseline 9, 10, 11

Clinical Management Algorithm

• The American Heart Association recommends checking current blood pressure control before initiating steroids, ensuring BP is at goal (<140/90 mmHg, or <130/80 mmHg if diabetic or high-risk) 8
• The American College of Cardiology advises against discontinuing clopidogrel for the steroid course unless there is active bleeding, and recommends continuing clopidogrel for its indicated duration based on the underlying cardiovascular condition 10, 12, 13

Important Caveats and Pitfalls

• The European Society of Cardiology warns against confusing short-term with long-term steroid risks, as the cardiovascular risks cited in rheumatology guidelines refer to chronic use (months to years), not 5-day courses 8, 14
• The American College of Cardiology recommends avoiding the addition of NSAIDs during the steroid course, as NSAIDs significantly increase bleeding risk when combined with clopidogrel 10
• The American Heart Association suggests considering alternative approaches or closer monitoring in high-risk scenarios, such as age ≥75 years with body weight <60 kg, history of peptic ulcer disease or prior GI bleeding, concomitant anticoagulation, or recent or planned surgery 12, 13